TAZORAC Drug Patent Profile
✉ Email this page to a colleague
When do Tazorac patents expire, and when can generic versions of Tazorac launch?
Tazorac is a drug marketed by Allergan and is included in two NDAs.
The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tazorac
A generic version of TAZORAC was approved as tazarotene by TARO on April 3rd, 2017.
Summary for TAZORAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 129 |
Clinical Trials: | 21 |
Patent Applications: | 5,802 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TAZORAC |
What excipients (inactive ingredients) are in TAZORAC? | TAZORAC excipients list |
DailyMed Link: | TAZORAC at DailyMed |
Recent Clinical Trials for TAZORAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bayer | Phase 2 |
Dana-Farber Cancer Institute | Phase 2 |
Dr. Reddy's Laboratories Limited | Phase 2 |
Pharmacology for TAZORAC
Drug Class | Retinoid |
Anatomical Therapeutic Chemical (ATC) Classes for TAZORAC
US Patents and Regulatory Information for TAZORAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | TAZORAC | tazarotene | CREAM;TOPICAL | 021184-001 | Sep 29, 2000 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-002 | Jun 13, 1997 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Allergan | TAZORAC | tazarotene | CREAM;TOPICAL | 021184-002 | Sep 29, 2000 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-001 | Jun 13, 1997 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TAZORAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-002 | Jun 13, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-001 | Jun 13, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-001 | Jun 13, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | TAZORAC | tazarotene | CREAM;TOPICAL | 021184-001 | Sep 29, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-002 | Jun 13, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-002 | Jun 13, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TAZORAC
See the table below for patents covering TAZORAC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2191773 | COMPOSITION DE GEL STABLE POUR LE TRAITEMENT TOPIQUE DE MALADIES DE LA PEAU (STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS) | ⤷ Try a Trial |
Luxembourg | 90227 | ⤷ Try a Trial | |
Denmark | 1147778 | ⤷ Try a Trial | |
Spain | 2034196 | ⤷ Try a Trial | |
Israel | 114049 | Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel | ⤷ Try a Trial |
Norway | 169489 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TAZORAC
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0031058 | 98C0008 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203 |
0284288 | SPC/GB98/002 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730 |
0284288 | 12/1998 | Austria | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |